July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Toni Choueiri: The work of Eddy Saad, Eli Van Allen, Sasha Gusev being highlighted here at ASCO24
May 26, 2024, 06:02

Toni Choueiri: The work of Eddy Saad, Eli Van Allen, Sasha Gusev being highlighted here at ASCO24

Toni Choueiri shared a post by Neeraj Agarwal on X/Twitter:

The work of Eddy Saad, Eli Van Allen, Sasha Gusev being highlighted here, ASCO24. We again validate SNP in IL-7 to be associated with irAEs!”

Quoting the post by Neeraj Agarwal:

Abstract #12140 ASCO24 by Eddy Saad.

Analysis of CheckMate 025 ph3 NIVO versus everolimus in patients with mRCC kidney cancer. Germline IL7 SNP associated with high rates of AEs in patents treated with NIVO but not with EVE.”

Source: Toni Choueiri/X and Neeraj Agarwal/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).

He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA.

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.